Search Results for "Fingolimod"
Original Source: Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis.
The discovery of fingolimod (FTY720/Gilenya; Novartis), an orally active immunomodulatory drug, has opened up new approaches to the treatment of multiple sclerosis, the most common inflammatory disorder of the central nervous system. Elucidation of the effects of fingolimod - mediated by the modulation of sphingosine 1-phosphate (S1P) receptors - has indicated that its therapeutic activity could be due to regulation of the migration of selected lymphocyte subsets into the central nervous system and direct e...
Matching Channels
None
Matching News
Fingolimod: 'Hint' of advantages in a small group of patients
The immunosuppressive drug fingolimod (trade name: Gilenya) is approved for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in adults. In an early benefit assessment pursu...
Fingolimod offers minor added benefit for patients with RRMS
The immunosuppressive drug fingolimod (trade name: Gilenya-) is approved for the treatment of highly-active relapsing-remitting multiple sclerosis (RRMS) in adults. In an early benefit assessment purs...
Fingolimod Reduces Disease Activity, Brain Atrophy in MS
MRI results from the pivotal FREEDOMS trial show that fingolimod reduced inflammatory lesion activity but also brain atrophy. Medscape Medical News
Data presented at the 65th annual meeting of the American Academy of Neurology (AAN) show Gilenya® (fingolimod), the first and only once-daily oral therapy reimbursed to treat highly active relapsing...
Study examines fingolimod therapy in patients with multiple sclerosis
The medication fingolimod reduced inflammatory lesion activity and reduced brain volume loss in patients with multiple sclerosis who participated in a two-year placebo-controlled clinical trial and we...
Patients with certain cardiovascular conditions should not take the multiple sclerosis drug fingolimod, and all patients starting the drug require careful monitoring for cardiac adverse events, accord...
Fingolimod could potentially eliminate or reduce progression of colitis-associated cancer
After uncovering a mechanism that promotes chronic intestinal inflammation and the development of colorectal cancer, scientists from Virginia Commonwealth University Massey Cancer Center have found th...
Early effects on MRI lesions, brain atrophy and relapses replicated across two large Phase III trials suggest substantial early treatment benefits of fingolimod1. Pooled analysis of core and long-term...
Matching PubMed Articles
Does fingolimod in multiple sclerosis patients cause macular edema?
Multiple sclerosis (MS) is a demyelinating disease of the central nervous system and is the common cause of optic neuritis. Fingolimod, an immunosuppressive agent, is used in MS to prevent acute exace...
The oral immunomodulator fingolimod (FTY720) has recently been shown to be highly effective in relapsing-remitting multiple sclerosis (MS). Fingolimod is a functional antagonist of the sphingosine-1-p...
INTRODUCTION. Fingolimod is the first approved drug with oral availability for the treatment of relapsing multiple sclerosis. AIMS. To review the mechanism of action of fingolimod and its relationship...
PURPOSE: Fingolimod (FTY720) is a sphingosine-1 phosphate-receptor (S1PR) modulator recently approved as a once-daily oral therapy for relapsing multiple sclerosis (MS) in many c...
Since April 2011 fingolimod (FTY 720, Gilenya®), a new oral treatment, is available for relapsing-remitting multiple sclerosis (MS) in Germany. Adverse effects in pre-marketing clinical controlled mu...
